Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT06735014 · University of Minnesota

Multicenter ALS Imaging Study

What this study is about

This is a multi-site study of ALS participants and healthy controls who will undergo brain and cervical spine MRIs and NfL blood testing at up-to 4 time points over the course of a year. The primary goal is to identify objective biomarkers of disease progression that are biologically relevant, linearly progressive, and sensitive to change.

View original scientific description

This is a multi-site study of ALS participants and healthy controls who will undergo brain and cervical spine MRIs and NfL blood testing at up-to 4 time points over the course of a year. The primary goal is to identify objective biomarkers of disease progression that are biologically relevant, linearly progressive, and sensitive to change.

Interventions

DIAGNOSTIC_TEST

Magnetic Resonance Imaging

Participants will undergo 3T MRI scanning of the brain and cervical spine MRIs

DIAGNOSTIC_TEST

Plasma neurofilament light chain (NfL) quantification

Participants will undergo a blood draw for the quantification of plasma neurofilament light chain

Primary outcome measures

Fiber Density

Time frame: Baseline, 3 months, 6 months, 12 months

This measure comes from the biophysical model used in brain imaging and is collected using MRI. It refers to the volume of the intra-axonal compartment per unit volume of the tissue. As this is a fraction it does not have a unit.

Fiber Cross-Section

Time frame: Baseline, 3 months, 6 months, 12 months

This measure comes from the biophysical model used in brain imaging and is collected using MRI. It refers to the change it fiber cross-section at the fiber bundle level when undergoing spatial normalization. This measure does not have a unit.

Orientation Dispersion

Time frame: Baseline, 3 months, 6 months, 12 months

This measure comes from the biophysical model used in brain imaging and is collected using MRI. Orientation dispersion is a measure of the uncertainty in the estimation of the fiber bundle orientation. It varies from 0 to 1 and does not have a unit. Higher values indicate greater uncertainty in estimation.

Intracellular Volume Fraction

Time frame: Baseline, 3 months, 6 months, 12 months

This measure comes from the biophysical model used in brain imaging and is collected using MRI. It is the proportion of the imaging voxel occupied by intracellular compartments. This ratio varies from 0 to 1 and does not have a unit. Larger values indicate greater density of intracellular compartments.

Free Water

Time frame: Baseline, 3 months, 6 months, 12 months

This measure comes from the biophysical model used in brain imaging and is collected using MRI. It represents the fractional volume of the free-water compartment. This is a ratio and it does not have a unit.

Cortical Thickness

Time frame: Baseline, 3 months, 6 months, 12 months

This measure is collected using MRI. It is the thickness of the cortical gray matter and is measured in millimeters.

Spinal Cord Cross-Sectional Area

Time frame: Baseline, 3 months, 6 months, 12 months

This measure is collected using MRI. It is the area of the spinal cord cross-section measured in millimeter square.

Spinal Cord Corticospinal Tract (CST) Fractional Anisotropy (FA)

Time frame: Baseline, 3 months, 6 months, 12 months

This measure is collected using MRI. It is a dimensionless scalar value between 0 and 1, indicating the degree of anisotropy (directionality) of water diffusion in the spinal cord's corticospinal tract. Higher values indicate higher anisotropy.

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • For participants with ALS:
  • \< 36 months since onset of symptoms
  • Definite, probable, lab supported-probable or possible ALS by El Escorial criteria OR definite, probable or possible ALS per Awaji-Shima Criteria
  • Forced vital capacity within the last 90 days ≥ 60% of the predicted value
  • Able to consent for themselves
  • Able to read and speak English
  • Clear of any contraindications for MRI Exclusion Criteria:
  • Individuals will be excluded if they have any condition that makes MRI unsafe or if they are unable to comply with instructions.
  • All participants will undergo a neurologic examination at enrollment. Control participants with clinically significant abnormal findings on neurological examination will be excluded from the study.

Exclusion criteria

  • Individuals will be excluded if they have any condition that makes MRI unsafe or if they are unable to comply with instructions.
  • All participants will undergo a neurologic examination at enrollment. Control participants with clinically significant abnormal findings on neurological examination will be excluded from the study.

Where

  • Gainesville, Florida
  • Evanston, Illinois
  • Minneapolis, Minnesota

Collaborators

Food and Drug Administration (FDA), Minnesota Office of Higher Education

Related conditions & keywords

Amyotrophic Lateral SclerosisALSMagnetic Resonance ImagingMRIALSFRS-RECASplasma neurofilament lightNfL

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced May 12, 2026 · Source of record for eligibility and locations

📊
1 of 90 participants interested
1% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

Gainesville

Florida

Location available
RECRUITING

Evanston

Illinois

Location available
RECRUITING

Minneapolis

Minnesota

Location available

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More ALS Trials by City

Browse all als clinical trials in these cities — not just this study.

Looking for Amyotrophic Lateral Sclerosis Treatment in Gainesville?

Join others in Florida exploring innovative treatment options through clinical research

Amyotrophic Lateral Sclerosis Treatment Options in Gainesville, Florida

If you're searching for Amyotrophic Lateral Sclerosis treatment in Gainesville, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Gainesville, Evanston, Minneapolis and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Amyotrophic Lateral Sclerosis. All study-related care is provided at no cost to participants.

Local Sites
3 locations in Florida
Now Enrolling
Up to 90 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Amyotrophic Lateral Sclerosis?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for Amyotrophic Lateral Sclerosis

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This Amyotrophic Lateral Sclerosis Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06735014. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.